Cargando…

Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies

The human epidermal growth factor receptor (HER1) and its partner HER2 are extensively described oncogenes and validated targets for cancer therapy. However, the effectiveness of monospecific therapies targeting these receptors is hampered by resistance emergence, which is frequently associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suárez, Narjara González, Báez, Gretchen Bergado, Rodríguez, Mabel Cruz, Pérez, Amelia Gutiérrez, García, Lisset Chao, Hernández Fernández, Diana Rosa, Pous, Judith Raymond, Ramírez, Belinda Sánchez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669935/ https://www.ncbi.nlm.nih.gov/pubmed/29137309 http://dx.doi.org/10.18632/oncotarget.19958

Ejemplares similares

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
por: Pérez-Martínez, Dayana, et al.
Publicado: (2022)

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
por: Choi, Byoungsan, et al.
Publicado: (2020)

Novel EXO-T vaccine using polyclonal CD4(+) T cells armed with HER2-specific exosomes for HER2-positive breast cancer
por: Li, Rong, et al.
Publicado: (2018)

Anti-Proliferative and Pro-Apoptotic Effects of Calligonum comosum (L’Her.) Methanolic Extract in Human Triple-Negative MDA-MB-231 Breast Cancer Cells
por: Alehaideb, Zeyad, et al.
Publicado: (2020)

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1
por: Campone, Mario, et al.
Publicado: (2011)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
por: Romaniello, Donatella, et al.
Publicado: (2020)

Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
por: Ren, Xiu-Rong, et al.
Publicado: (2012)

Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines
por: Mansouri-Fard, Samaneh, et al.
Publicado: (2020)

HER2 Phosphorylates and Destabilizes Pro-Apoptotic PUMA, Leading to Antagonized Apoptosis in Cancer Cells
por: Carpenter, Richard L., et al.
Publicado: (2013)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
por: Reddy, Tejaswini P., et al.
Publicado: (2020)

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
por: Moasser, Mark M.
Publicado: (2022)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
por: Kuroiwa, Yuka, et al.
Publicado: (2020)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022)

Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer
por: Zambrano, Joelle, et al.
Publicado: (2016)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer
por: Muñoz-Moreno, Laura, et al.
Publicado: (2016)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models
por: Mansur, Ameer, et al.
Publicado: (2023)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

In her family /
por: Metheny, Pat
Publicado: (1987)

An Essential Difference between the Flavonoids MonoHER and Quercetin in Their Interplay with the Endogenous Antioxidant Network
por: Jacobs, Hilde, et al.
Publicado: (2010)

ADVICE TO THE EXPECTANT MOTHER ON THE CARE OF HER HEALTH AND THAT OF HER CHILD
Publicado: (1947)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1947)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1943)

Advice to the Expectant Mother on the Care of Her Health and That of Her Child
Publicado: (1941)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lg2gh5o5h7b2ei4dn8gdntne26